Corcept Therapeutics rises 7% after UBS upgrade Corcept Therapeutics jumped more than 7% on Wednesday. The upgrade to Buy from Neutral by UBS Group also included a raised price target to $72 from $44. This implies nearly 41% upside from Tuesday's close of $51.16.
Corcept Therapeutics rises 7% after UBS upgrade
Corcept Therapeutics jumped more than 7% on Wednesday.
The upgrade to Buy from Neutral by UBS Group also included a raised price target to $72 from $44.
This implies nearly 41% upside from Tuesday’s close of $51.16.
